Research and technologies
Secarta Technology: Redefining T-cell recognition and tumor attack mechanisms
Key Drivers of Success:
Off-Target Toxicity Is Critical For FDA Approval
Successful cell therapy hinges on achieving robust T-cell–mediated tumor attack at the maximum tolerated dose (MTD).
Clinical experience reveals striking multi-log differences in MTD across modalities
—approximately 10¹² for TIL therapy, 5 × 10⁹ for TCR-T, and 2 × 10⁸ for CAR-T—underscoring the critical impact of platform design on therapeutic dosing potential.
.png)
Secarta Technology:
Redfining T-cell recognition and tumor attack mechanisms
Our Technology Empowers T Cells To
Eradicate Cancer - Not Just Fight It
.png)
*** Based on preclinical studies
Our Cell Therapy Demonstrates
No evidence of off-target toxicity***
*** Based on preclinical studies
.png)
CAR-T 1.0
Unsuccessful Lethal off-target toxicity
CAR-T 1.0
FDA-approved Acceptable toxicity
CAR-T 2.0
No off-target toxicity***
Syntracta-T 3.0
No off-target toxicity***
Clinically-Failed
Developments
Currently FDA-
Approved CARs
Secarta-Bio
CAR T2.0
Secarta-Bio
Syntracta 3.0
*** Based on preclinical studies
Secarta Tech achieves clinically validated level of T-cell activation
Jurkat-NFAT-GFP reporter assay.
•Clinically validated T-cell activation is defined as the activation level of FDA-approved CD19 (FMC63) CAR to target B cell tumors.
•Cancer cells that naturally express intracellular L5.
•HEK293L5-TM-OE: overexpress a recombinant artificial L5-CD8TM (trans-membrane) fusion protein so that cells are positive for artificial membrane-bound L5.
